- Published on
Toxicology – Alpha-Blocker Toxicity
Source
Alpha-adrenergic blockers include medications such as prazosin, terazosin, doxazosin, and tamsulosin. These drugs are used in the management of hypertension, benign prostatic hyperplasia (BPH), post-traumatic stress disorder (PTSD), and certain anxiety conditions.
Typical Presentation
Toxicity often presents with episodes of dizziness or fainting, especially after standing. Patients may report weakness and lightheadedness following overdose or excessive dosing.
Clinical Features
Common symptoms include orthostatic (postural) hypotension, dizziness, syncope, headache, nausea, generalized weakness, palpitations, and reflex tachycardia. These effects are primarily due to vasodilation and reduced vascular tone.
Mechanism of Action
Alpha-blockers inhibit alpha-adrenergic receptors. Blockade of α1 receptors leads to relaxation of vascular smooth muscle, resulting in decreased peripheral resistance and blood pressure. This vasodilation causes venous pooling, particularly when standing, leading to orthostatic hypotension. Because there is no direct suppression of cardiac function, the body compensates with reflex tachycardia.
Management
Treatment is supportive. Intravenous fluids are used to restore circulating volume. Positioning the patient supine or in the Trendelenburg position can help improve blood pressure. Activated charcoal may be considered in early presentations.
Key Points
Source
Alpha-adrenergic blockers include medications such as prazosin, terazosin, doxazosin, and tamsulosin. These drugs are used in the management of hypertension, benign prostatic hyperplasia (BPH), post-traumatic stress disorder (PTSD), and certain anxiety conditions.
Typical Presentation
Toxicity often presents with episodes of dizziness or fainting, especially after standing. Patients may report weakness and lightheadedness following overdose or excessive dosing.
Clinical Features
Common symptoms include orthostatic (postural) hypotension, dizziness, syncope, headache, nausea, generalized weakness, palpitations, and reflex tachycardia. These effects are primarily due to vasodilation and reduced vascular tone.
Mechanism of Action
Alpha-blockers inhibit alpha-adrenergic receptors. Blockade of α1 receptors leads to relaxation of vascular smooth muscle, resulting in decreased peripheral resistance and blood pressure. This vasodilation causes venous pooling, particularly when standing, leading to orthostatic hypotension. Because there is no direct suppression of cardiac function, the body compensates with reflex tachycardia.
Management
Treatment is supportive. Intravenous fluids are used to restore circulating volume. Positioning the patient supine or in the Trendelenburg position can help improve blood pressure. Activated charcoal may be considered in early presentations.
Key Points
- Orthostatic hypotension is a hallmark feature of toxicity.
- Reflex tachycardia occurs due to compensatory mechanisms.
- Tamsulosin is more selective for α1 receptors in the urinary tract and typically has less effect on systemic blood pressure at therapeutic doses.
- Published on
Toxicology – ACE Inhibitor Toxicity
Source
Angiotensin-converting enzyme (ACE) inhibitors include medications such as captopril, enalapril, lisinopril, ramipril, quinapril, fosinopril, benazepril, moexipril, and trandolapril. They are widely used to treat hypertension, heart failure, and diabetic kidney disease.
Typical Presentation
Toxicity may occur due to accidental or intentional overdose, particularly in elderly patients with multiple medications. Patients commonly present with low blood pressure and electrolyte abnormalities.
Clinical Features
Key findings include hypotension, acute kidney injury (manifesting as reduced urine output or elevated creatinine), and hyperkalemia. Elevated potassium levels can lead to cardiac conduction abnormalities and arrhythmias. In some cases, bradycardia may occur. Even at therapeutic doses, ACE inhibitors may cause cough, wheezing, and angioedema.
Mechanism of Action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, resulting in decreased vasoconstriction and lower blood pressure. They also increase levels of bradykinin, which contributes to side effects such as cough and angioedema.
Management
Treatment is supportive. Intravenous fluids are typically effective for hypotension. Continuous cardiac monitoring and ECG evaluation are recommended. Laboratory monitoring should include kidney function and serum potassium. Activated charcoal may be considered in early presentations.
Hyperkalemia should be treated as indicated, using measures such as insulin with glucose, beta-agonists, potassium-binding agents, or dialysis in severe cases. Calcium gluconate or calcium chloride is used to stabilize cardiac membranes when ECG changes are present.
Angioedema requires immediate discontinuation of the drug and treatment with supportive measures, including antihistamines and corticosteroids. Airway protection may be necessary in severe cases.
Key Points
Source
Angiotensin-converting enzyme (ACE) inhibitors include medications such as captopril, enalapril, lisinopril, ramipril, quinapril, fosinopril, benazepril, moexipril, and trandolapril. They are widely used to treat hypertension, heart failure, and diabetic kidney disease.
Typical Presentation
Toxicity may occur due to accidental or intentional overdose, particularly in elderly patients with multiple medications. Patients commonly present with low blood pressure and electrolyte abnormalities.
Clinical Features
Key findings include hypotension, acute kidney injury (manifesting as reduced urine output or elevated creatinine), and hyperkalemia. Elevated potassium levels can lead to cardiac conduction abnormalities and arrhythmias. In some cases, bradycardia may occur. Even at therapeutic doses, ACE inhibitors may cause cough, wheezing, and angioedema.
Mechanism of Action
ACE inhibitors block the conversion of angiotensin I to angiotensin II, resulting in decreased vasoconstriction and lower blood pressure. They also increase levels of bradykinin, which contributes to side effects such as cough and angioedema.
Management
Treatment is supportive. Intravenous fluids are typically effective for hypotension. Continuous cardiac monitoring and ECG evaluation are recommended. Laboratory monitoring should include kidney function and serum potassium. Activated charcoal may be considered in early presentations.
Hyperkalemia should be treated as indicated, using measures such as insulin with glucose, beta-agonists, potassium-binding agents, or dialysis in severe cases. Calcium gluconate or calcium chloride is used to stabilize cardiac membranes when ECG changes are present.
Angioedema requires immediate discontinuation of the drug and treatment with supportive measures, including antihistamines and corticosteroids. Airway protection may be necessary in severe cases.
Key Points
- Angioedema can occur unpredictably, even after prolonged use.
- Chronic dry cough is a common side effect of ACE inhibitors.
- Angiotensin receptor blockers (ARBs) are less likely to cause cough or angioedema.
- Published on
Toxicology – Clonidine Toxicity
Source
Clonidine is available as oral tablets and transdermal patches. It is commonly prescribed for hypertension, attention-deficit/hyperactivity disorder (ADHD), and management of opioid withdrawal.
Typical Presentation
Toxicity often occurs after accidental ingestion, particularly in children. Patients may present with rapid onset of sedation and cardiovascular depression.
Clinical Features
Key findings include hypotension, bradycardia, slow respiratory rate (bradypnea), hypothermia, pinpoint pupils (miosis), and altered mental status ranging from lethargy to coma. A brief phase of elevated blood pressure may occur early due to peripheral receptor effects.
Mechanism of Action
Clonidine is a central alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased heart rate and blood pressure. In overdose, its lipophilic nature allows rapid central nervous system penetration. Transient hypertension may occur initially due to stimulation of peripheral alpha-1 receptors before central effects dominate.
Management
Treatment is supportive and includes close monitoring of cardiac and respiratory status. Airway protection and intravenous fluids are essential. Most cases improve within 24 hours. High-dose naloxone may be beneficial in some patients. Whole bowel irrigation should be considered if a transdermal patch has been ingested.
Key Points
Source
Clonidine is available as oral tablets and transdermal patches. It is commonly prescribed for hypertension, attention-deficit/hyperactivity disorder (ADHD), and management of opioid withdrawal.
Typical Presentation
Toxicity often occurs after accidental ingestion, particularly in children. Patients may present with rapid onset of sedation and cardiovascular depression.
Clinical Features
Key findings include hypotension, bradycardia, slow respiratory rate (bradypnea), hypothermia, pinpoint pupils (miosis), and altered mental status ranging from lethargy to coma. A brief phase of elevated blood pressure may occur early due to peripheral receptor effects.
Mechanism of Action
Clonidine is a central alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, leading to decreased heart rate and blood pressure. In overdose, its lipophilic nature allows rapid central nervous system penetration. Transient hypertension may occur initially due to stimulation of peripheral alpha-1 receptors before central effects dominate.
Management
Treatment is supportive and includes close monitoring of cardiac and respiratory status. Airway protection and intravenous fluids are essential. Most cases improve within 24 hours. High-dose naloxone may be beneficial in some patients. Whole bowel irrigation should be considered if a transdermal patch has been ingested.
Key Points
- Clonidine toxicity can resemble opioid overdose due to sedation and pinpoint pupils.
- Early transient hypertension may precede hypotension.
- Abrupt discontinuation in chronic users can lead to rebound hypertension.
- Published on
Toxicology – Beta-Blocker Toxicity
Source
Beta-blockers include medications such as propranolol, metoprolol, atenolol, nadolol, pindolol, labetalol, and carvedilol. These drugs are commonly used to manage hypertension, cardiac arrhythmias, angina, migraines, and anxiety-related conditions.
Typical Presentation
Toxicity may occur after accidental ingestion (especially in children) or intentional overdose. Patients often present with cardiovascular depression and altered mental status.
Clinical Features
Common findings include bradycardia, hypotension, and varying degrees of heart block. More severe toxicity may lead to ventricular arrhythmias, seizures (especially with propranolol), and central nervous system depression. Additional features can include widened QRS complexes (notably with propranolol), QT prolongation (e.g., with sotalol), and hypoglycemia.
Mechanism of Action
Beta-blockers inhibit β-adrenergic receptors. Blockade of β1 receptors reduces heart rate and contractility, leading to decreased cardiac output. β2 receptor blockade can result in bronchoconstriction. Lipophilic agents, particularly propranolol, cross the blood–brain barrier and can cause central nervous system effects such as sedation, confusion, and seizures.
Management
Treatment is supportive with continuous cardiac monitoring. Interventions may include intravenous fluids, glucagon (to increase intracellular cAMP independent of β-receptors), high-dose insulin therapy with glucose, vasopressors, and cardiac pacing if needed. Sodium bicarbonate may be used for QRS widening, and magnesium for QT prolongation. Lipid emulsion therapy can be considered in severe cases. Bronchodilators are used if bronchospasm develops. Whole bowel irrigation may be indicated for sustained-release ingestions.
Key Points
Source
Beta-blockers include medications such as propranolol, metoprolol, atenolol, nadolol, pindolol, labetalol, and carvedilol. These drugs are commonly used to manage hypertension, cardiac arrhythmias, angina, migraines, and anxiety-related conditions.
Typical Presentation
Toxicity may occur after accidental ingestion (especially in children) or intentional overdose. Patients often present with cardiovascular depression and altered mental status.
Clinical Features
Common findings include bradycardia, hypotension, and varying degrees of heart block. More severe toxicity may lead to ventricular arrhythmias, seizures (especially with propranolol), and central nervous system depression. Additional features can include widened QRS complexes (notably with propranolol), QT prolongation (e.g., with sotalol), and hypoglycemia.
Mechanism of Action
Beta-blockers inhibit β-adrenergic receptors. Blockade of β1 receptors reduces heart rate and contractility, leading to decreased cardiac output. β2 receptor blockade can result in bronchoconstriction. Lipophilic agents, particularly propranolol, cross the blood–brain barrier and can cause central nervous system effects such as sedation, confusion, and seizures.
Management
Treatment is supportive with continuous cardiac monitoring. Interventions may include intravenous fluids, glucagon (to increase intracellular cAMP independent of β-receptors), high-dose insulin therapy with glucose, vasopressors, and cardiac pacing if needed. Sodium bicarbonate may be used for QRS widening, and magnesium for QT prolongation. Lipid emulsion therapy can be considered in severe cases. Bronchodilators are used if bronchospasm develops. Whole bowel irrigation may be indicated for sustained-release ingestions.
Key Points
- Lipophilic beta-blockers can cause early and significant central nervous system depression.
- Hypoglycemia is more commonly seen compared to calcium channel blocker toxicity.
- Bronchospasm may occur, particularly in patients with underlying respiratory disease.
- Published on
Toxicology – Calcium Channel Blocker Toxicity
Source
Calcium channel blockers (CCBs) include medications such as verapamil, diltiazem, amlodipine, nifedipine, nicardipine, and felodipine. These drugs are commonly prescribed for conditions like hypertension, arrhythmias, angina, migraines, and Raynaud’s phenomenon.
Typical Presentation
Toxicity often occurs after accidental ingestion, especially in children, or intentional overdose. Patients may present with cardiovascular instability along with gastrointestinal symptoms.
Clinical Features
Key findings include bradycardia, varying degrees of heart block, hypotension, nausea, vomiting, constipation, and ileus. Hyperglycemia is a distinguishing feature due to impaired insulin release. Severe cases may involve altered mental status secondary to reduced cerebral perfusion.
Mechanism of Action
CCBs inhibit L-type calcium channels in cardiac and smooth muscle. In vascular smooth muscle, this leads to vasodilation and hypotension. In the heart, they decrease sinoatrial and atrioventricular nodal conduction (negative chronotropic effect) and reduce contractility (negative inotropic effect). In pancreatic cells, calcium channel blockade decreases insulin secretion, resulting in elevated blood glucose levels.
Management
Treatment is supportive and requires close cardiac monitoring. Interventions may include intravenous fluids, calcium (calcium gluconate or calcium chloride), high-dose insulin therapy with glucose supplementation, glucagon, vasopressors, and lipid emulsion therapy in severe cases. Whole bowel irrigation may be considered for sustained-release ingestions. Advanced measures such as transvenous pacing or intra-aortic balloon pump support may be required in refractory cases.
Key Points
Source
Calcium channel blockers (CCBs) include medications such as verapamil, diltiazem, amlodipine, nifedipine, nicardipine, and felodipine. These drugs are commonly prescribed for conditions like hypertension, arrhythmias, angina, migraines, and Raynaud’s phenomenon.
Typical Presentation
Toxicity often occurs after accidental ingestion, especially in children, or intentional overdose. Patients may present with cardiovascular instability along with gastrointestinal symptoms.
Clinical Features
Key findings include bradycardia, varying degrees of heart block, hypotension, nausea, vomiting, constipation, and ileus. Hyperglycemia is a distinguishing feature due to impaired insulin release. Severe cases may involve altered mental status secondary to reduced cerebral perfusion.
Mechanism of Action
CCBs inhibit L-type calcium channels in cardiac and smooth muscle. In vascular smooth muscle, this leads to vasodilation and hypotension. In the heart, they decrease sinoatrial and atrioventricular nodal conduction (negative chronotropic effect) and reduce contractility (negative inotropic effect). In pancreatic cells, calcium channel blockade decreases insulin secretion, resulting in elevated blood glucose levels.
Management
Treatment is supportive and requires close cardiac monitoring. Interventions may include intravenous fluids, calcium (calcium gluconate or calcium chloride), high-dose insulin therapy with glucose supplementation, glucagon, vasopressors, and lipid emulsion therapy in severe cases. Whole bowel irrigation may be considered for sustained-release ingestions. Advanced measures such as transvenous pacing or intra-aortic balloon pump support may be required in refractory cases.
Key Points
- Mental status may initially remain normal despite significant cardiovascular compromise.
- Hyperglycemia helps differentiate CCB toxicity from beta-blocker overdose.
- ECG findings may include PR prolongation, sinus arrest, or high-grade heart block.
- Atropine may be attempted for bradycardia but is often ineffective.
- Published on
Toxicology – Fire Ant (Formicidae) Envenomation
Source
Ants belong to the Formicidae family within the Hymenoptera order. Fire ants, particularly the red imported fire ant (RIFA), are an aggressive invasive species commonly found in the southern United States. These ants live in large, highly organized colonies and can attack in groups when disturbed.
Typical Presentation
Envenomation typically occurs when a person disturbs an ant mound, leading to multiple simultaneous stings. Victims often report sudden intense burning pain followed by visible skin lesions.
Clinical Features
Each sting produces immediate pain and a small raised wheal. Within 24 hours, these lesions evolve into characteristic pustules. The affected areas are often itchy, and scratching may lead to secondary infection or scarring. In some individuals, especially those with hypersensitivity, systemic allergic reactions including anaphylaxis may occur.
Mechanism of Action
Fire ant venom contains alkaloid compounds, particularly piperidine derivatives, which cause local tissue irritation and inflammation. The venom also includes components capable of triggering allergic responses in susceptible individuals.
Management
Treatment involves removal from the exposure source and supportive care. Topical corticosteroids and oral antihistamines can help relieve inflammation and itching. In cases of allergic reactions, appropriate management—including epinephrine for anaphylaxis—should be initiated. Antibiotics may be required if secondary infection develops.
Key Points
Source
Ants belong to the Formicidae family within the Hymenoptera order. Fire ants, particularly the red imported fire ant (RIFA), are an aggressive invasive species commonly found in the southern United States. These ants live in large, highly organized colonies and can attack in groups when disturbed.
Typical Presentation
Envenomation typically occurs when a person disturbs an ant mound, leading to multiple simultaneous stings. Victims often report sudden intense burning pain followed by visible skin lesions.
Clinical Features
Each sting produces immediate pain and a small raised wheal. Within 24 hours, these lesions evolve into characteristic pustules. The affected areas are often itchy, and scratching may lead to secondary infection or scarring. In some individuals, especially those with hypersensitivity, systemic allergic reactions including anaphylaxis may occur.
Mechanism of Action
Fire ant venom contains alkaloid compounds, particularly piperidine derivatives, which cause local tissue irritation and inflammation. The venom also includes components capable of triggering allergic responses in susceptible individuals.
Management
Treatment involves removal from the exposure source and supportive care. Topical corticosteroids and oral antihistamines can help relieve inflammation and itching. In cases of allergic reactions, appropriate management—including epinephrine for anaphylaxis—should be initiated. Antibiotics may be required if secondary infection develops.
Key Points
- Fire ant stings often occur in clusters due to coordinated attacks.
- Lesions typically progress from wheals to pustules within a day.
- Scratching increases the risk of infection and scarring.
- Severe allergic reactions, although less common, can be life-threatening.
- Published on
Toxicology – Hymenoptera Envenomation (Bees, Wasps, Hornets)
Source
Hymenoptera are winged insects that include bees, wasps, hornets, and ants. The Vespidae family (wasps, yellow jackets, hornets) tend to be more aggressive, while the Apidae family (honeybees, bumblebees) are generally less aggressive unless provoked.
Typical Presentation
Patients may present after one or multiple stings, often occurring outdoors. Severe reactions are more likely in cases of multiple stings or in individuals with allergic sensitivity.
Clinical Features
Local reactions include pain, redness, swelling, and warmth at the sting site. Systemic reactions may involve widespread hives (urticaria), wheezing, shortness of breath, chest discomfort, nausea, vomiting, airway swelling (stridor), altered mental status, and in severe cases, shock or coagulopathy. Anaphylaxis can occur even after a single sting in sensitized individuals.
Mechanism of Action
Venom from these insects contains substances such as melittin, histamine, phospholipases, and other mediators that trigger inflammation and mast cell activation. This can lead to allergic reactions ranging from mild to life-threatening.
Management
Treatment is supportive. Any retained stingers should be promptly removed by scraping to prevent further venom release. Anaphylaxis requires immediate administration of epinephrine. Additional therapies may include antihistamines, corticosteroids, intravenous fluids, and inhaled beta-agonists for respiratory symptoms.
Key Points
Source
Hymenoptera are winged insects that include bees, wasps, hornets, and ants. The Vespidae family (wasps, yellow jackets, hornets) tend to be more aggressive, while the Apidae family (honeybees, bumblebees) are generally less aggressive unless provoked.
Typical Presentation
Patients may present after one or multiple stings, often occurring outdoors. Severe reactions are more likely in cases of multiple stings or in individuals with allergic sensitivity.
Clinical Features
Local reactions include pain, redness, swelling, and warmth at the sting site. Systemic reactions may involve widespread hives (urticaria), wheezing, shortness of breath, chest discomfort, nausea, vomiting, airway swelling (stridor), altered mental status, and in severe cases, shock or coagulopathy. Anaphylaxis can occur even after a single sting in sensitized individuals.
Mechanism of Action
Venom from these insects contains substances such as melittin, histamine, phospholipases, and other mediators that trigger inflammation and mast cell activation. This can lead to allergic reactions ranging from mild to life-threatening.
Management
Treatment is supportive. Any retained stingers should be promptly removed by scraping to prevent further venom release. Anaphylaxis requires immediate administration of epinephrine. Additional therapies may include antihistamines, corticosteroids, intravenous fluids, and inhaled beta-agonists for respiratory symptoms.
Key Points
- These stings are a leading cause of fatal envenomation, primarily due to anaphylaxis.
- Severe reactions can occur even with a single sting in allergic individuals.
- Honeybees typically leave behind a barbed stinger, whereas wasps and hornets can sting multiple times.
- Published on
Toxicology – Cone Snail Envenomation
Source
Cone snails are marine predators found in warm and tropical oceans worldwide. There are hundreds of species, many with brightly patterned shells. They use a specialized harpoon-like structure (radula) to inject venom into prey or humans when handled.
Typical Presentation
Exposure typically occurs when a person handles or steps on a cone snail. Patients often report an immediate stinging or burning sensation at the site of contact, followed by progressive neurological symptoms.
Clinical Features
Initial symptoms include localized pain similar to an insect sting, along with burning, numbness, and tingling. As toxicity progresses, patients may develop muscle weakness, difficulty swallowing, blurred vision, and spreading numbness (including lips and tongue). Severe cases can lead to paralysis, shock, and respiratory failure. Some systemic effects may be delayed.
Mechanism of Action
Cone snail venom contains a mixture of peptide toxins known as conotoxins. These compounds primarily affect ion channels and disrupt nerve signaling, leading to neuromuscular dysfunction and paralysis.
Management
There is no specific antidote. Treatment is supportive, with close monitoring of airway and respiratory function. Mechanical ventilation may be required in severe cases until the toxin is cleared. Most symptoms improve within several hours.
Key Points
- Even minor contact can result in envenomation.
- Symptoms may progress from local pain to life-threatening paralysis.
- Some conotoxins are being studied for potential medical applications.
- Although rare, fatalities have been reported.
- Published on
Toxicology – Hyperkalemia (Elevated Potassium Levels)
Source
Elevated potassium levels can result from potassium supplements, kidney failure (especially in dialysis patients), and certain medications such as ACE inhibitors, NSAIDs, and potassium-sparing diuretics. It may also occur due to cellular breakdown in conditions like rhabdomyolysis, hemolysis, or tumor lysis syndrome.
Typical Presentation
Patients may present with vague symptoms such as weakness or fatigue, but serious cases often involve cardiac abnormalities detected on ECG, especially in those with impaired kidney function.
Clinical Features
Symptoms are often nonspecific and may include:
High extracellular potassium alters the electrical gradient across cardiac cells, making them more excitable and prone to dangerous arrhythmias.
Management
Treatment is urgent and involves three main strategies:
Source
Elevated potassium levels can result from potassium supplements, kidney failure (especially in dialysis patients), and certain medications such as ACE inhibitors, NSAIDs, and potassium-sparing diuretics. It may also occur due to cellular breakdown in conditions like rhabdomyolysis, hemolysis, or tumor lysis syndrome.
Typical Presentation
Patients may present with vague symptoms such as weakness or fatigue, but serious cases often involve cardiac abnormalities detected on ECG, especially in those with impaired kidney function.
Clinical Features
Symptoms are often nonspecific and may include:
- Generalized weakness and malaise
- Slow heart rate (bradycardia)
- Cardiac arrhythmias
- Peaked T waves
- Prolonged PR interval
- Flattened or absent P waves
- Widened QRS complex
- “Sine wave” pattern leading to cardiac arrest
High extracellular potassium alters the electrical gradient across cardiac cells, making them more excitable and prone to dangerous arrhythmias.
Management
Treatment is urgent and involves three main strategies:
- Stabilize the heart
- IV calcium (calcium gluconate or calcium chloride) to protect cardiac membranes
- Shift potassium into cells
- Insulin with glucose
- β-agonists (e.g., high-dose nebulized albuterol)
- Sodium bicarbonate (in cases of acidosis)
- Remove potassium from the body
- Dialysis (most effective in severe cases)
- Potassium-binding resins (e.g., sodium polystyrene sulfonate)
- ECG monitoring is essential in suspected hyperkalemia.
- Calcium does not lower potassium—it stabilizes the heart.
- Severe hyperkalemia is a medical emergency due to risk of fatal arrhythmias.
- Kidney function plays a major role in potassium regulation.
- Published on
Toxicology – Lithium Toxicity
Source
Lithium carbonate is commonly prescribed for bipolar disorder. It is also used in industrial settings, including fireworks production.
Typical Presentation
Toxicity may occur from acute overdose, chronic accumulation, or a combination of both. Patients on long-term therapy are especially at risk if kidney function declines or if interacting medications are introduced.
Clinical Features
Lithium toxicity presents in three main patterns:
Lithium affects multiple intracellular pathways, including inhibition of signaling systems and neurotransmitter modulation. It is eliminated almost entirely by the kidneys, making renal function a key factor in toxicity.
Management
Treatment is supportive and focuses on enhancing elimination:
Source
Lithium carbonate is commonly prescribed for bipolar disorder. It is also used in industrial settings, including fireworks production.
Typical Presentation
Toxicity may occur from acute overdose, chronic accumulation, or a combination of both. Patients on long-term therapy are especially at risk if kidney function declines or if interacting medications are introduced.
Clinical Features
Lithium toxicity presents in three main patterns:
- Acute toxicity: Predominantly gastrointestinal symptoms such as nausea, vomiting, diarrhea, and dizziness. Kidney injury and mild cardiac changes (e.g., QT prolongation) may occur.
- Chronic toxicity: Mainly neurological symptoms including tremor, weakness, hyperreflexia, involuntary movements, poor coordination, confusion, and altered consciousness, which can progress to coma.
- Acute-on-chronic toxicity: A combination of both GI and neurological symptoms, often more severe.
Lithium affects multiple intracellular pathways, including inhibition of signaling systems and neurotransmitter modulation. It is eliminated almost entirely by the kidneys, making renal function a key factor in toxicity.
Management
Treatment is supportive and focuses on enhancing elimination:
- IV fluids to improve kidney perfusion and promote excretion
- Whole bowel irrigation for sustained-release ingestion
- Hemodialysis for severe cases (e.g., high lithium levels, neurological symptoms, or kidney impairment)
-
- Toxicity risk increases with dehydration, kidney dysfunction, and certain medications (e.g., NSAIDs, ACE inhibitors).
- Neurological symptoms are more prominent in chronic toxicity.
- Lithium levels may rise again after dialysis, requiring repeated treatments.
- Activated charcoal is not effective for lithium overdose.
- Therapeutic levels are typically 0.6–1.2 mEq/L.
